The 12-week human clinical trial began in early June 2024 and set out to investigate if, through these mechanisms of action, ...

Poor bowel preparation also led to repeat colonoscopies for 18.9% of current GLP-1RA users, compared to 11.1% of controls ...

Pendulum Therapeutics latest innovation comes in the form of a GLP-1 probiotic, acting as an appetite suppressor and healthy ...

Semaglutide offers a multifaceted approach to type 2 diabetes treatment, enhancing insulin release and reducing blood sugar ...

Diabetes and weight-loss drug tirzepatide (Mounjaro, Zepbound) was listed as a contributing factor in the death of a 58-year-old nurse from Scotland who died of multiple organ failure, septic shock, ...

Novo Nordisk said the side effects in trials so far for its experimental obesity drug CagriSema were similar to its GLP-1 ...

Following a disappointing earnings showing from Eli Lilly last week, Novo Nordisk’s latest report on the performance of its ...

LifeVantage (LFVN) announced results from a human clinical trial performed on the new MindBody GLP-1 System. Results from the trial included a ...

You may have heard about — or maybe even experienced — the short-term side effects of Ozempic® — such as nausea, vomiting, ...

ETNB has a solid financial runway but faces risks from GLP-1 data and competition within the FGF21 space, making it a Hold ...

Hanmi Presents Three Breakthrough Findings on Novel Obesity Drugs at 2024 ObesityWeek High Quality Obesity Management by ...

Ω* The 12-week human clinical trial began in early June 2024 and set out to investigate if, through these mechanisms of action, the MindBody GLP-1 System could holistically and sustainably ...